Therapeutic Asset Ratings

tt-4

Tulmimetostat

Ubamatamab

XS-02

Atezolizumab

prt3645

rp903

NC 410

Adu-1805

ai-061

Alta2618

Amt-151

asp1893

Atv-1601

Atx-559

autologous CD3+ enriched T lymphocytes obtained from peripheral blood mononuclear cells (PBMCs) by apheresis. The cells are transduced with a self-inactivating, non-replicating lentiviral vector encoding an enhanced-affinity T cell receptor (TCR) targeting the HLA-A*02:01-restricted MAGE-A4 peptide (GVYDGREHTV) alongside the CD8 alpha (CD8?) co-receptor. The expressed transgene comprises the coding sequence for the CD8? co-receptor, separated by a foot-and-mouth disease virus 2A self-cleaving peptide sequence from the coding sequence of the MAGE-A4 T-cell receptor alpha and beta chains that are separated from each other by a porcine teschovirus-1 2A self-cleaving peptide sequence, under control of the human elongation factor 1 alpha (EF-1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a tRNA primer binding site, a ? packaging signal, a truncated gag, a Rev response element (RRE) and a central polypurine tract (cPPT) sequence 5' to the transgene, and a polypurine tract (PPT) 3' to the transgene. The vector is pseudotyped with the vesicular stomatitis virus (VSV) G envelope glycoprotein. The CD3+ T lymphocytes are purified and activated using anti-CD3/anti-CD28 monoclonal antibody coated magnetic beads. The cells are then cultured in media containing interleukin 2 (IL-2), human AB serum and a protein kinase B (AKT inhibitor). The cells are CD3+ (> 80%), express the high affinity MAGE-A4 specific TCR and CD8? co-receptor (CD8? +TCR+; >16%) and are cytotoxic to MAGE-A4 expressing tumor cells

AZD0240

azd0240: autologous, engineered t cells targeting kras g12d

Balstilimab

bg-68501

Bgb-43395

bl0175

Bl-M07D1

Botensilimab

bp1001-a